Senior Research Fellow, SFI Starter Investigator Research Grant (SIRG) fellow

 

Research Groups

Cancer Research Group

Contact

Phone:+353 (01) 700 5912
Email: naomi.walsh@dcu.ie

Principal Research Interests

Dr. Walsh's current research is focused on developing organotypic 3D cancer models to define and validate the biological consequences of genomic variants of pancreatic cancer. Her research aims to understand the development of pancreatic cancer, to uncover markers for early detection and to identify those at high risk of pancreatic cancer.

Other interests include understanding the tumour diversity caused by genomic alterations which contributes to cancer resistance to chemotherapy and molecular targeted therapies in breast and melanoma. Her lab uses genomic and functional NGS approaches to identify the mechanisms of genomic and immunological diversity to develop prognostic/predictive signatures and therapeutic strategies to overcome treatment resistance.

Selected Publications

  1. Gullo G, Walsh N, Fennelly D, Bose R, Walshe J, Tryfonopoulos D, O'Mahony K, Hammond L, Silva N, McDonnell D, Ballot J, Quinn C, McDermott EW, Evoy D, Prichard R, Geraghty J, Amstrong J, Crown J. Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project. Br J Cancer. 2018 May 18. doi: 10.1038/s41416-018-0114-x. [Epub ahead of print] PubMed PMID: 29773838.
  2. Noro R*, Ishigame T*, Walsh N*, Shiraishi K, Robles AI, Ryan BM, Schetter AJ, Bowman ED, Welsh JA, Seike M, Gemma A, Skaug V, Mollerup S, Haugen A, Yokota J, Kohno T, Harris CC. A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts. J Thorac Oncol. 2017 Jan;12(1):65-76. doi: 10.1016/j.jtho.2016.08.141. Epub 2016 Sep 6. PubMed PMID: 27613525. *Joint first authorship
  3. Walsh N, Kennedy S, Larkin A, Corkery B, O'Driscoll L, Clynes M, Crown J, O'Donovan N. EGFR and HER2 inhibition in pancreatic cancer. Invest New Drugs.2013 Jun;31(3):558-66. doi: 10.1007/s10637-012-9891-x. Epub 2012 Oct 18. PubMed PMID: 23076814.
  4. Walsh N, Larkin A, Swan N, Conlon K, Dowling P, McDermott R, Clynes M. RNAiknockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation. Cancer Lett. 2011 Jul 28;306(2):180-9. doi: 10.1016/j.canlet.2011.03.004. Epub 2011 Apr 5. PubMed PMID: 21470770.
  5. Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, Ooi W, Gullo G, Crown J, Clynes M, O'Driscoll L. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 2009 Jun 24;9:6. doi: 10.1186/1471-2490-9-6. PubMed PMID: 19552816; PubMed Central PMCID: PMC2723136.

Awards

Irish Cancer Society Researcher of the Year 2017

Share

EnglishJapanese